SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
633.00    13.00 (2.10%)
Bid:
631.00
Ask:
633.00
Spread: 2.00 (0.317%)
Market Cap: £551.50m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Director/PDMR Shareholding

12 Feb 2026 15:26

RNS Number : 8282S
Victrex PLC
12 February 2026
 

12 February 2026

Victrex plc

Grant of Nil-Cost Options

On 12 February 2026 (the "Grant Date") the Company granted awards in the form of nil-cost options over a total of 318,449 ordinary shares in Victrex to Dr. James Routh, Chief Executive Officer, comprising:

 

(a) three standalone awards over the number of shares specified in the table below, which reflect three long-term incentive awards forfeited by Dr Routh as a result of him ceasing to be an employee of his previous employer, AB Dynamics plc, in order to join Victrex, as agreed as part of his recruitment package (the "Buyout Awards")

 

 

Number of Victrex shares

Normal Vesting Date*

Part 1 of the 2023 LTIP Buy-Out Award

25,530

4 December 2025

2024 LTIP Buy-Out Award

54,538

8 February 2027

2025 LTIP Buy-Out Award

66,380

29 November 2027

 

\* The Awards will vest on the later of their Normal Vesting Date and the date on which the extent of achievement against the applicable performance conditions is determined and approved by the Victrex Remuneration Committee.

 

(b) two awards under the Victrex 2019 Long Term Incentive Plan (the "LTIP") over 21,501 Shares ("Part 2 of the 2023 LTIP Buy-Out Award") and 150,500 Shares (the "2026 LTIP Award").

 

Buyout award terms

 

The buy-out arrangements were structured in accordance with the principles set out in the Company's approved Directors' Remuneration Policy, in particular that they are limited to a reasonable estimate of value of remuneration lost when leaving the former employer and reflect the delivery mechanism, time horizons and performance requirements attached to that remuneration. The structure of the awards mirrors what was forfeited on leaving AB Dynamics, and the conversion into Victrex shares on joining provides alignment with Victrex shareholders. The Buyout Awards (including Part 2 of the 2023 LTIP Buy-Out Award) are, therefore, subject to the same performance conditions (where applicable) and post-vesting holding periods as the forfeited AB Dynamics LTIP awards. Further details will be contained within the 2026 Directors' Remuneration Report.

 

The Buyout Awards (including Part 2 of the 2023 LTIP Buy-Out Award) will become exercisable on the same dates as the awards they replace (provided the Company's remuneration committee can assess the extent to which the performance conditions are met) and any shares acquired are subject to the same holding periods.

 

The number of ordinary shares over which the Buyout Awards were granted was based on the mid-market closing share price of Victrex and AB Dynamics plc on 31 December 2025, being the latest dealing date prior to Dr. Routh commencing employment with Victrex on 1 January 2026.

The exercise of the Buyout Awards will not be satisfied with an issue of shares or a transfer of treasury shares.

2026 LTIP Award

The 2026 LTIP Award has been granted with a value representing 175% of Dr Routh's base salary as at the Grant Date.

The 2026 LTIP Award will vest based on the achievement of EPS, TSR, ROIC and sustainability targets over a 3-year performance period. The detailed performance conditions will be provided in the 2026 Directors' Remuneration Report. The 2026 LTIP Award is subject to a holding period ending on the fifth anniversary of the date of grant.

The number of shares over which the 2026 LTIP Award was granted was calculated based on a share price of £6.9767, being the mid-market price quoted over a three-day average immediately preceding the Grant Date.

Notes:

As a result of these transactions, Dr. James Routh holds options over 318,449 ordinary shares in the Company.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

Enquiries:

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG +44 (0) 7809 595831

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aircraft and cars to energy operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, enable environmental and societal benefit for our customers and drive value for our shareholders. Find out more at www.victrexplc.com

Registered Office: Victrex Technology Centre, Hillhouse International, Thornton Cleveleys, Lancashire, FY5 4QD

Registered Number: 2793780, England and Wales

 

Buyout Awards

1.

Details of the person discharging managerial responsibilities/person closely associated

(a)

Name

James Routh

2.

Reason for the notification

(a)

Position/status

Chief Executive Officer

(b)

Initial notification/ Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

(a)

Name

Victrex plc

(b)

LEI

213800UYNPHAUNHPXL67

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(a)

Description of the Financial Instrument

Nil-cost options over ordinary shares of 1p each

Identification code of the Financial Instrument

GB0009292243

(b)

Nature of the transaction

Grant of nil-cost options to acquire ordinary shares in the Company in compensation for awards forfeited on leaving former employer

(c)

Price(s) and volume(s)

Price(s)

Volume

Nil

25,530

Nil

54,538

Nil

66,380

(d)

Aggregated information:

- Aggregated volume

 

- Price

 

N/A

Nil

(e)

Date of the transaction

12 February 2026

(f)

Place of the transaction

Outside a trading venue

 

 

2026 LTIP Award

1.

Details of the person discharging managerial responsibilities/person closely associated

(a)

Name

James Routh

2.

Reason for the notification

(a)

Position/status

Chief Executive Officer

(b)

Initial notification/ Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

(a)

Name

Victrex plc

(b)

LEI

213800UYNPHAUNHPXL67

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(a)

Description of the Financial Instrument

Nil-cost options over ordinary shares of 1p each

Identification code of the Financial Instrument

GB0009292243

(b)

Nature of the transaction

Grant of two LTIP awards (in the form of nil-cost options to acquire ordinary shares in the Company)

 

(c)

Price(s) and volume(s)

Price(s)

Volume

Nil

21,501

Nil

150,500

(d)

Aggregated information:

- Aggregated volume

 

- Price

 

N/A

Nil

(e)

Date of the transaction

12 February 2026

(f)

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZZGMZKZKGVZM
Date   Source Headline
24th Jun 20249:44 amRNSHolding(s) in Company
14th Jun 20249:00 amRNSAdditional Listing
3rd Jun 20242:19 pmRNSBlock listing Interim Review
3rd Jun 20249:30 amRNSDirector/PDMR Shareholding
31st May 202411:23 amRNSTotal Voting Rights
23rd May 20247:00 amRNSSBTI approval of carbon reduction targets
15th May 20243:59 pmRNSDirector/PDMR Shareholding
14th May 20244:05 pmRNSDirector/PDMR Shareholding
13th May 20247:00 amRNSVictrex plc - Interim Results 2024
7th May 20243:25 pmRNSDirector Declaration
30th Apr 20242:54 pmRNSTotal Voting Rights
28th Mar 20249:56 amRNSTotal Voting Rights
15th Mar 20248:30 amRNSDirectorate Change
6th Mar 20242:06 pmRNSDirector/PDMR Shareholding
29th Feb 20249:36 amRNSTotal Voting Rights
21st Feb 20248:00 amRNSBlock listing Interim Review
9th Feb 202412:16 pmRNSResult of AGM
9th Feb 20247:00 amRNSAGM & Q1 Interim Management Statement
31st Jan 202412:26 pmRNSTotal Voting Rights
25th Jan 202410:57 amRNSHolding(s) in Company
9th Jan 202412:13 pmRNSAnnual Report & Accounts
29th Dec 20239:00 amRNSTotal Voting Rights
12th Dec 202310:21 amRNSDirector/PDMR Shareholding
5th Dec 20232:42 pmRNSDirector/PDMR Shareholding
5th Dec 20232:33 pmRNSDirector/PDMR Shareholding
5th Dec 20237:00 amRNSVictrex plc - Preliminary Results 2023
1st Dec 202310:41 amRNSBlock listing Interim Review
30th Nov 202311:10 amRNSTotal Voting Rights
3rd Nov 20231:31 pmRNSHolding(s) in Company
31st Oct 20239:36 amRNSTotal Voting Rights
19th Sep 20231:59 pmRNSDirector/PDMR Shareholding
8th Sep 20239:32 amRNSHolding(s) in Company
31st Aug 20239:30 amRNSTotal Voting Rights
23rd Aug 202310:52 amRNSHolding(s) in Company
17th Aug 20231:27 pmRNSDirector/PDMR Shareholding
31st Jul 20239:39 amRNSTotal Voting Rights
18th Jul 202311:51 amRNSDirector/PDMR Shareholding
13th Jul 20232:00 pmRNSAdditional Listing
6th Jul 20237:00 amRNSVictrex plc - Q3 Interim Management Statement
3rd Jul 20234:03 pmRNSHolding(s) in Company
30th Jun 20239:37 amRNSTotal Voting Rights
27th Jun 202310:08 amRNSDirector/PDMR Shareholding
19th Jun 20232:27 pmRNSDirector/PDMR Shareholding
14th Jun 20237:00 amRNSTrading Statement
1st Jun 202312:08 pmRNSBlock listing Interim Review
31st May 20239:52 amRNSTotal Voting Rights
17th May 202310:55 amRNSDirector/PDMR Shareholding
16th May 202310:03 amRNSDirector/PDMR Shareholding
12th May 202310:37 amRNSDirector/PDMR Shareholding
11th May 202312:01 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.